Vitamin B12: What Your Number Changes About Your Treatment

What Vitamin B12 Actually Measures

Serum B12 quantifies total circulating cobalamin, the water-soluble vitamin responsible for DNA synthesis, red blood cell formation, and myelin maintenance in nerve tissue. The test captures both active (holotranscobalamin) and inactive protein-bound fractions, which means a "normal" total B12 can still coexist with functional deficiency at the cellular level [1].

Most reference laboratories report a normal range of 200 to 900 pg/mL (148 to 664 pmol/L). That spread is wide. A person sitting at 210 pg/mL is technically within range but may already have subclinical deficiency with elevated methylmalonic acid (MMA) concentrations. The American Academy of Family Physicians (AAFP) recommends treating the clinical picture, not the number alone, and using MMA or homocysteine as secondary markers when B12 falls between 200 and 400 pg/mL [2]. Levels below 200 pg/mL are considered definitively low and typically warrant immediate supplementation regardless of symptoms.

The distinction matters because B12 deficiency is both common and frequently missed. A Framingham Offspring Study analysis found that 39% of participants had plasma B12 concentrations in the "low normal" range (200 to 399 pg/mL), and nearly 9% were frankly deficient [3]. These are not small numbers. They represent a population where medications, diet, and absorption problems converge to create real clinical risk.

How B12 Levels Change Medication Decisions

A B12 result below 400 pg/mL should trigger a review of every medication on the patient's list. Several common drug classes deplete B12, and the downstream effects can mimic or worsen the very conditions those drugs treat.

Metformin is the most studied offender. The Diabetes Prevention Program (DPP) Outcomes Study followed participants for a mean of 13 years and found that long-term metformin use was associated with a twofold increase in biochemical B12 deficiency compared to placebo. At the study's end, 4.3% of metformin users had B12 levels below 203 pg/mL versus 2.3% in the placebo group [4]. The American Diabetes Association (ADA) 2024 Standards of Care now state: "Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with anemia or peripheral neuropathy" [5].

Proton pump inhibitors (PPIs) like omeprazole and pantoprazole present a second common risk. By suppressing gastric acid, PPIs impair the cleavage of B12 from dietary proteins. A Kaiser Permanente study of 25,956 patients with B12 deficiency found that PPI use for two or more years was associated with a 65% increased risk of deficiency (OR 1.65, 95% CI 1.58 to 1.73) [6]. Histamine-2 receptor antagonists carried a similar but smaller risk.

Other medications that warrant B12 monitoring include colchicine, cholestyramine, and certain anticonvulsants. The clinical action is straightforward: if B12 is declining and the drug is necessary, add supplementation rather than discontinue the medication.

The Gray Zone: 200 to 400 pg/mL

This is where clinical judgment earns its keep. A B12 of 350 pg/mL in a 28-year-old vegetarian taking no medications is a different clinical scenario than the same number in a 64-year-old on metformin and a PPI.

When B12 lands between 200 and 400 pg/mL, the next step is measuring serum methylmalonic acid. MMA rises when intracellular B12 is insufficient for the enzymatic conversion of methylmalonyl-CoA to succinyl-CoA. An MMA level above 0.4 µmol/L in a patient with borderline B12 confirms functional deficiency with high specificity [7]. Homocysteine is less specific because it also rises with folate deficiency, B6 deficiency, and renal impairment.

Dr. Sally Stabler, whose work at the University of Colorado defined much of the modern diagnostic approach, has written: "Reliance on serum cobalamin alone will miss a substantial proportion of patients with clinically significant deficiency" [7]. This observation, published in the New England Journal of Medicine, underpins the current two-tier testing strategy used by most endocrinologists and internists.

The practical rule: if the patient has any neurological symptoms (numbness, tingling, balance problems, cognitive changes) and a B12 between 200 and 400 pg/mL, order MMA. Do not wait for the B12 to drop below 200.

B12 Deficiency and Neuropathy: A Diagnostic Trap

Peripheral neuropathy in a diabetic patient is almost reflexively attributed to hyperglycemia. That reflex costs some patients months or years of appropriate treatment. B12 deficiency produces a neuropathy that is clinically indistinguishable from diabetic peripheral neuropathy: symmetric, length-dependent, affecting the feet before the hands, with burning, numbness, and impaired vibration sense [8].

The overlap creates a specific diagnostic trap for metformin-treated type 2 diabetes patients. The drug that controls their glucose simultaneously depletes the vitamin whose deficiency mimics the complication of uncontrolled glucose. A 2019 meta-analysis of 29 studies (N = 8,089) published in the Journal of Clinical Endocrinology and Metabolism confirmed that metformin-associated B12 deficiency significantly increased the odds of peripheral neuropathy (OR 2.07, 95% CI 1.28 to 3.35) [9].

The clinical instruction is direct. Every diabetic patient with peripheral neuropathy should have B12 and MMA checked before the neuropathy is assumed to be purely glycemic in origin. If B12 is low or borderline and MMA is elevated, a three-to-six-month trial of B12 supplementation should precede or accompany any neuropathy-specific intervention. Some patients experience partial or complete symptom reversal. Others do not, particularly when diagnosis has been delayed beyond 12 months.

Cognitive Symptoms and B12: What the Evidence Supports

B12 deficiency can produce cognitive slowing, difficulty concentrating, and memory complaints that overlap with early dementia presentations. The pathophysiology involves impaired methylation reactions needed for myelin repair and neurotransmitter synthesis.

A prospective study in Neurology (N = 271 community-dwelling adults aged 65 to 102) found that participants with low B12 levels at baseline had a faster rate of brain volume loss over five years compared to those with higher levels [10]. The Oxford OPTIMA trial showed that B-vitamin supplementation (including B12) slowed the rate of brain atrophy by 30% in older adults with elevated homocysteine, with the greatest benefit in those with baseline homocysteine above 13 µmol/L [11].

These findings do not mean B12 supplementation prevents Alzheimer's disease. That claim exceeds the evidence. What the data support is this: in a patient presenting with cognitive complaints and a B12 below 400 pg/mL, measuring MMA and initiating a repletion trial before pursuing expensive neuroimaging or starting cholinesterase inhibitors is both cost-effective and clinically reasonable. The Endocrine Society does not publish a formal B12 screening guideline, but the AAFP's 2017 clinical review explicitly recommends B12 evaluation in all patients presenting with cognitive decline [2].

How to Raise a Low B12

The right repletion strategy depends on the cause and severity of the deficiency.

Oral supplementation works for most patients with diet-related or medication-induced deficiency. A randomized trial in the British Journal of Clinical Pharmacology demonstrated that oral cyanocobalamin at 1,000 mcg daily was as effective as intramuscular injections for correcting B12 deficiency in patients without pernicious anemia or malabsorption (mean B12 increase: 136 pg/mL vs. 119 pg/mL at 90 days, P = 0.17) [12]. This finding changed practice. Oral dosing is now first-line for most outpatient deficiency.

Intramuscular injections remain necessary for patients with pernicious anemia (autoimmune destruction of intrinsic factor), post-bariatric surgery malabsorption, or severe deficiency with neurological symptoms. The typical loading protocol is 1,000 mcg IM daily for 7 days, then weekly for 4 weeks, then monthly for maintenance [2].

Sublingual formulations (methylcobalamin or cyanocobalamin, 1,000 to 5,000 mcg) are used by patients who prefer to avoid injections and have normal absorption. Evidence for sublingual versus oral absorption is limited, and most professional guidelines do not distinguish between the two routes.

Dietary sources alone rarely correct established deficiency. A single 3-ounce serving of clams provides approximately 84 mcg of B12 (3,500% of the daily value), but most animal-source foods deliver far less per serving. Fortified cereals, nutritional yeast, and fortified plant milks can help maintain adequate levels in vegetarians and vegans, but therapeutic repletion requires supplemental doses.

For metformin users: the ADA does not recommend stopping metformin for B12 deficiency. The recommended approach is concurrent oral B12 supplementation at 1,000 mcg daily while continuing metformin at the prescribed dose [5].

When a High B12 Raises Concerns

An unexpectedly elevated B12 (above 1,000 pg/mL) in a patient not taking supplements is not reassuring. It may indicate hepatocellular damage, myeloproliferative disorders, or chronic kidney disease.

The liver stores 1 to 5 mg of B12, representing a two-to-five-year reserve. Hepatocyte damage releases stored B12 into the bloodstream, producing paradoxically high serum levels. A French cohort study of 3,702 patients found that B12 levels above 1,275 pg/mL in non-supplemented individuals were associated with increased one-year mortality, driven primarily by hepatic disease and solid-organ cancers [13]. The authors concluded that "an elevated cobalamin level should prompt investigation for underlying disease rather than reassurance."

Chronic myelogenous leukemia and polycythemia vera can raise B12 through increased production of transcobalamin-binding proteins by proliferating white blood cells. Renal impairment raises B12 because the kidney is the primary site of holotranscobalamin clearance.

The clinical takeaway: a high B12 in a patient who is not supplementing warrants a hepatic panel, complete blood count with differential, and renal function testing. It should not be ignored.

Monitoring Frequency and Practical Thresholds

How often to check B12 depends on the patient's risk profile.

For metformin users, the ADA recommends baseline B12 measurement at initiation and periodic monitoring thereafter [5]. "Periodic" is not precisely defined; many clinicians check annually. Patients on doses of 1,500 mg per day or higher, those with pre-existing borderline B12, and those over age 65 warrant more frequent testing (every 6 months).

For PPI users, B12 testing is reasonable after 12 to 24 months of continuous therapy and annually thereafter if the PPI is continued. No major gastroenterology society has issued a formal screening mandate, but the clinical rationale is well supported by the Kaiser Permanente data showing significant risk after two years of PPI use [6].

For patients with pernicious anemia on maintenance injections, B12 levels should be checked 1 to 2 months after initiating the maintenance phase, then annually to confirm adequacy.

For post-bariatric surgery patients, the American Society for Metabolic and Bariatric Surgery (ASMBS) recommends lifelong annual B12 monitoring, with MMA added if levels fall below 400 pg/mL.

The goal of treatment is not to maximize the number. A target range of 400 to 700 pg/mL provides adequate cellular cobalamin for most patients without requiring dose escalation. MMA normalization (below 0.4 µmol/L) is the better functional endpoint for confirming that repletion has succeeded at the tissue level.